O
NERV icon

OrbiMed’s Minerva Neurosciences NERV Stock Holding History

OrbiMed’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-43,022
Closed -$3.05M – 149
2017
Q2 		$3.05M Sell
43,022
-45,016
-51% -$2.91M 0.03% 125
2017
Q1 		$5.71M Buy
88,038
+18,513
+27% +$1.44M 0.06% 112
2016
Q4 		$6.54M Hold
69,525
– – 0.08% 103
2016
Q3 		$7.85M Buy
69,525
+29,337
+73% +$2.85M 0.09% 112
2016
Q2 		$3.28M Buy
+40,188
New +$2.56M 0.03% 117

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed's NERV Position: Q3 2017 in Review

OrbiMed sold out of Minerva Neurosciences (NERV) in Q3 2017, closing a stake of 43,022 shares — an estimated $3.05M sold.

OrbiMed first reported a position in NERV in Q2 2016 and held it in 5 quarters. The position peaked at $7.85M in Q3 2016. 70 funds tracked by Wall St. Rank hold NERV as of Q3 2017.

  • OrbiMed reported no remaining Minerva Neurosciences position as of Q3 2017 after selling out during the quarter.
  • OrbiMed sold 43,022 Minerva Neurosciences shares in Q3 2017, an estimated $3.05M.
  • OrbiMed first reported a position in Minerva Neurosciences in Q2 2016 and held it in 5 quarters.
  • OrbiMed's Minerva Neurosciences position peaked at $7.85M in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2017.

Based on OrbiMed's 13F filing for Q3 2017, filed 14 Nov 2017.